Bosentan vs Macitentan

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Pulmonary Arterial Hypertension

Shared mechanism: Endothelin receptor (ETA/ETB, dual) · full Pulmonary Arterial Hypertension pipeline

Bosentan · Tracleer

Marketed by Johnson & Johnson and partners

Approved in Pulmonary Arterial Hypertensionsmall molecule
Partial signal

NCT00091715 · Phase 3 · completed

The study was randomized and quadruple-blinded, with a placebo control and 185 participants. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Reported efficacy

exercise capacity (Baseline to end of study); cardiac hemodynamics (Baseline to end of study): Co-primary endpoints at month 6: pulmonary vascular resistance treatment effect -22.6% vs placebo (p<0.0001); 6-min walk distance (exercise capacity) treatment effect +19.1 m vs placebo (p=0.0758, not significant) (mixed)

Result source: NCT00091715

Macitentan · Opsumit

Marketed by Johnson & Johnson

Approved in Pulmonary Arterial Hypertensionsmall molecule
Partial signal

NCT02932410 · Phase 3 · completed

The study randomized 148 children aged 2 years or older to open-label macitentan or standard care, but it was not blinded, and additional children younger than 2 years or enrolled in China received macitentan without randomization. The posted primary endpoints were pharmacokinetic blood concentrations rather than clinical outcomes, with no formal treatment comparison; clinical disease-progression results remain unreported.

Reported efficacy

Time to First Confirmed Morbidity or Mortality Event up to the End of Treatment (Kaplan-Meier Estimate of Patients Without a Morbidity or Mortality Event) (Up to end of treatment (data presented up to month 36)): Time to First Confirmed Morbidity or Mortality Event up to the End of Treatment (Kaplan-Meier Estimate of Patients Without a Morbidity or Mortality Event) (Up to end of treatment (data presented up to month 36)): ACT-064992 3 mg — Kaplan-Meier estimate at Month 6: 89.3 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 12: 81.6 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 18: 72.5 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 24: 65.5 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 30: 61.9 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 36: 55 percentage of participants-Kaplan Meier | ACT-064992 10 mg — Kaplan-Meier estimate at Month 6: 92.7 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 12: 85.5 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 18: 79.9 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 24: 74.3 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 30: 70 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 36: 63.2 percentage of participants-Kaplan Meier vs Placebo — Kaplan-Meier estimate at Month 6: 80.1 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 12: 71.4 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 18: 61.5 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 24: 57.3 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 30: 50.2 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 36: 47 percentage of participants-Kaplan Meier (met)

Result source: NCT00660179

Results for Pulmonary Arterial Hypertension

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Coverage. Bosentan: 7 of 7 rows · Macitentan: 7 of 7 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricBosentan
Rows use multiple source trials
Macitentan
Rows use multiple source trials
6MWD - Change
absolute change · m
14.08 vs 17.42 placebo m @ 12wka,b,c,d
NCT00323297 · Phase 4 · registry result, not featured evidence
12.5 vs -9.4 placebo m @ 26wk10 mge,a,b,c,d
NCT00660179 · Phase 3 · monotherapy · Pulmonary Arterial Hypertension · phase 3
show 1 more dose
7.4 vs -9.4 placebo m @ 26wk3 mg
NCT00660179 · Phase 3 · monotherapy · Pulmonary Arterial Hypertension · phase 3
Borg Dyspnea
absolute change · score
-0.73 vs 0.16 placebo score @ 12wka,f,c,g
NCT00323297 · Phase 4 · registry result, not featured evidence
-0.22 vs -0.29 placebo score @ 16wka,f,c,g
NCT01743001 · Phase 3 · registry result, not featured evidence
WHO FC Worsening
event count · % of participants
No placebo or comparator arm
Worsened WHO FC
15.2% (n=33) @ 78wk*2mg/kg b.i.d.e,h,b,c,i
NCT01338415 · Phase 3 · registry result, not featured evidence · converted to % from 5 Participants as posted
show 1 more dose
9.7% (n=31) @ 78wk*2mg/kg t.i.d.
NCT01338415 · Phase 3 · registry result, not featured evidence · converted to % from 3 Participants as posted
1.1% (n=87) @ 26wk*10 mgh,b,c,i
Worsened WHO FC
NCT02310672 · Phase 4 · registry result, not featured evidence · converted to % from 1 Participants as posted
Dropout rate
52.2%j
NCT00303459 · Phase 4 · registry result, not featured evidence
show 13 more results
14%
NCT00323297 · Phase 4 · registry result, not featured evidence
5.4%
NCT00367770 · Phase 4 · registry result, not featured evidence
30.3%2mg/kg b.i.d.
NCT01338415 · Phase 3 · registry result, not featured evidence
—2mg/kg t.i.d
NCT01338415 · Phase 3 · registry result, not featured evidence
29%2mg/kg t.i.d.
NCT01338415 · Phase 3 · registry result, not featured evidence
—2 mg/kg b.i.d.
NCT01223352 · Phase 3 · registry result, not featured evidence
0%2 mg/kg b.i.d.
NCT01223352 · Phase 3 · registry result, not featured evidence
—2 mg/kg t.i.d.
NCT01223352 · Phase 3 · registry result, not featured evidence
0%2 mg/kg t.i.d.
NCT01223352 · Phase 3 · registry result, not featured evidence
—400 mg/Day
NCT01392469 · Phase 3 · registry result, not featured evidence · combination
—200 mg/Day
NCT01392469 · Phase 3 · registry result, not featured evidence · combination
—
NCT00319020 · Phase 3 · registry result, not featured evidence
0%
NCT01721564 · Phase na · registry result, not featured evidence
0%China Single-arm Cohort (>=12 to <k
NCT02932410 · Phase 3 · Hypertension, Pulmonary Arterial Hypertension · phase 3
show 10 more results
11.1%Macitentan (JNJ-67896062) (<2 Year
NCT02932410 · Phase 3 · background therapy · Hypertension, Pulmonary Arterial Hypertension · phase 3
19.2%Macitentan (JNJ-67896062) (>=2 Yea
NCT02932410 · Phase 3 · Hypertension, Pulmonary Arterial Hypertension · phase 3
—Macitentan (JNJ67896062) (<2 Years
NCT02932410 · Phase 3 · Hypertension, Pulmonary Arterial Hypertension · phase 3
16.9%10 mg
NCT00660179 · Phase 3 · monotherapy · Pulmonary Arterial Hypertension · phase 3
23.2%3 mg
NCT00660179 · Phase 3 · monotherapy · Pulmonary Arterial Hypertension · phase 3
39.3%10 mg
NCT00667823 · Phase 3 · monotherapy
17.2%10 mg
NCT02310672 · Phase 4 · registry result, not featured evidence
0%
NCT05167825 · Phase 3 · registry result, not featured evidence
2.6%
NCT01743001 · Phase 3 · registry result, not featured evidence
15.2%
NCT01841762 · Phase 3 · registry result, not featured evidence
Discontinued due to AEs
—j
NCT00303459 · Phase 4 · registry result, not featured evidence
show 13 more results
4%
NCT00323297 · Phase 4 · registry result, not featured evidence
2.7%
NCT00367770 · Phase 4 · registry result, not featured evidence
24.2%2mg/kg b.i.d.
NCT01338415 · Phase 3 · registry result, not featured evidence
—2mg/kg t.i.d
NCT01338415 · Phase 3 · registry result, not featured evidence
19.4%2mg/kg t.i.d.
NCT01338415 · Phase 3 · registry result, not featured evidence
—2 mg/kg b.i.d.
NCT01223352 · Phase 3 · registry result, not featured evidence
—2 mg/kg b.i.d.
NCT01223352 · Phase 3 · registry result, not featured evidence
—2 mg/kg t.i.d.
NCT01223352 · Phase 3 · registry result, not featured evidence
—2 mg/kg t.i.d.
NCT01223352 · Phase 3 · registry result, not featured evidence
—400 mg/Day
NCT01392469 · Phase 3 · registry result, not featured evidence · combination
—200 mg/Day
NCT01392469 · Phase 3 · registry result, not featured evidence · combination
—
NCT00319020 · Phase 3 · registry result, not featured evidence
—
NCT01721564 · Phase na · registry result, not featured evidence
—China Single-arm Cohort (>=12 to <k
NCT02932410 · Phase 3 · Hypertension, Pulmonary Arterial Hypertension · phase 3
show 10 more results
—Macitentan (JNJ-67896062) (<2 Year
NCT02932410 · Phase 3 · background therapy · Hypertension, Pulmonary Arterial Hypertension · phase 3
—Macitentan (JNJ-67896062) (>=2 Yea
NCT02932410 · Phase 3 · Hypertension, Pulmonary Arterial Hypertension · phase 3
—Macitentan (JNJ67896062) (<2 Years
NCT02932410 · Phase 3 · Hypertension, Pulmonary Arterial Hypertension · phase 3
—10 mg
NCT00660179 · Phase 3 · monotherapy · Pulmonary Arterial Hypertension · phase 3
—3 mg
NCT00660179 · Phase 3 · monotherapy · Pulmonary Arterial Hypertension · phase 3
1.3%10 mg
NCT00667823 · Phase 3 · monotherapy
—10 mg
NCT02310672 · Phase 4 · registry result, not featured evidence
—
NCT05167825 · Phase 3 · registry result, not featured evidence
—
NCT01743001 · Phase 3 · registry result, not featured evidence
—
NCT01841762 · Phase 3 · registry result, not featured evidence
Serious AEs
45.9%j
NCT00303459 · Phase 4 · registry result, not featured evidence
show 13 more results
44%
NCT00323297 · Phase 4 · registry result, not featured evidence
18.9%
NCT00367770 · Phase 4 · registry result, not featured evidence
45.5%2mg/kg b.i.d.
NCT01338415 · Phase 3 · registry result, not featured evidence
41.9%2mg/kg t.i.d
NCT01338415 · Phase 3 · registry result, not featured evidence
—2mg/kg t.i.d.
NCT01338415 · Phase 3 · registry result, not featured evidence
12.1%2 mg/kg b.i.d.
NCT01223352 · Phase 3 · registry result, not featured evidence
—2 mg/kg b.i.d.
NCT01223352 · Phase 3 · registry result, not featured evidence
19.4%2 mg/kg t.i.d.
NCT01223352 · Phase 3 · registry result, not featured evidence
—2 mg/kg t.i.d.
NCT01223352 · Phase 3 · registry result, not featured evidence
5.6%400 mg/Day
NCT01392469 · Phase 3 · registry result, not featured evidence · combination
10.5%200 mg/Day
NCT01392469 · Phase 3 · registry result, not featured evidence · combination
50%
NCT00319020 · Phase 3 · registry result, not featured evidence
0%
NCT01721564 · Phase na · registry result, not featured evidence
12.5%China Single-arm Cohort (>=12 to <k
NCT02932410 · Phase 3 · Hypertension, Pulmonary Arterial Hypertension · phase 3
show 10 more results
—Macitentan (JNJ-67896062) (<2 Year
NCT02932410 · Phase 3 · background therapy · Hypertension, Pulmonary Arterial Hypertension · phase 3
36.1%Macitentan (JNJ-67896062) (>=2 Yea
NCT02932410 · Phase 3 · Hypertension, Pulmonary Arterial Hypertension · phase 3
44.4%Macitentan (JNJ67896062) (<2 Years
NCT02932410 · Phase 3 · Hypertension, Pulmonary Arterial Hypertension · phase 3
45%10 mg
NCT00660179 · Phase 3 · monotherapy · Pulmonary Arterial Hypertension · phase 3
52%3 mg
NCT00660179 · Phase 3 · monotherapy · Pulmonary Arterial Hypertension · phase 3
64.4%10 mg
NCT00667823 · Phase 3 · monotherapy
17.2%10 mg
NCT02310672 · Phase 4 · registry result, not featured evidence
28.6%
NCT05167825 · Phase 3 · registry result, not featured evidence
6.1%
NCT01743001 · Phase 3 · registry result, not featured evidence
17.3%
NCT01841762 · Phase 3 · registry result, not featured evidence
Most frequent reported AEs
j
oedema peripheral 18.9% (placebo 14.9%)
headache 15.1% (placebo 13.8%)
cough 13.8% (placebo 12.1%)
NCT00303459 · Phase 4 · registry result, not featured evidence
show 9 more results
diarrhoea 14% (placebo 9.4%)
headache 14% (placebo 13.2%)
oedema peripheral 14% (placebo 15.1%)
NCT00323297 · Phase 4 · registry result, not featured evidence
oedema peripheral 18.9%
nasopharyngitis 13.5%
chest pain 10.8%
NCT00367770 · Phase 4 · registry result, not featured evidence
2mg/kg b.i.d.
upper respiratory tract infection 27.3%
nasopharyngitis 18.2%
pyrexia 15.2%
NCT01338415 · Phase 3 · registry result, not featured evidence
2mg/kg t.i.d
upper respiratory tract infection 41.9%
pyrexia 22.6%
diarrhoea 19.4%
NCT01338415 · Phase 3 · registry result, not featured evidence
2 mg/kg b.i.d.
upper respiratory tract infection 18.2%
nasopharyngitis 15.2%
pyrexia 12.1%
NCT01223352 · Phase 3 · registry result, not featured evidence
2 mg/kg t.i.d.
upper respiratory tract infection 35.5%
pyrexia 19.4%
diarrhoea 12.9%
NCT01223352 · Phase 3 · registry result, not featured evidence
400 mg/Day
vomiting 22.2%
anaemia 16.7%
blood potassium decreased 16.7%
NCT01392469 · Phase 3 · registry result, not featured evidence · combination
200 mg/Day
diarrhoea 26.3%
nausea 21.1%
back pain 10.5%
NCT01392469 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 19.4%
abdominal pain 16.7%
bronchitis 13.9%
NCT00319020 · Phase 3 · registry result, not featured evidence
k
cough 12.5%
influenza 12.5%
iron deficiency 12.5%
NCT02932410 · Phase 3 · Hypertension, Pulmonary Arterial Hypertension · phase 3
show 9 more results
upper respiratory tract infection 30.6%
headache 19.4%
nasopharyngitis 19.4%
NCT02932410 · Phase 3 · Hypertension, Pulmonary Arterial Hypertension · phase 3
upper respiratory tract infection 44.4%
covid-19 22.2%
gastroenteritis 22.2%
NCT02932410 · Phase 3 · Hypertension, Pulmonary Arterial Hypertension · phase 3
10 mg
oedema peripheral 18.2% (placebo 18.1%)
upper respiratory tract infection 15.3% (placebo 12.9%)
nasopharyngitis 14% (placebo 10.4%)
NCT00660179 · Phase 3 · monotherapy · Pulmonary Arterial Hypertension · phase 3
3 mg
upper respiratory tract infection 19.2% (placebo 12.9%)
oedema peripheral 16% (placebo 18.1%)
nasopharyngitis 14.8% (placebo 10.4%)
NCT00660179 · Phase 3 · monotherapy · Pulmonary Arterial Hypertension · phase 3
10 mg
upper respiratory tract infection 22%
nasopharyngitis 19.1%
oedema peripheral 19.1%
NCT00667823 · Phase 3 · monotherapy
10 mg
oedema peripheral 21.8%
headache 20.7%
dizziness 13.8%
NCT02310672 · Phase 4 · registry result, not featured evidence
nasopharyngitis 85.7%
pyrexia 57.1%
adenovirus infection 42.9%
NCT05167825 · Phase 3 · registry result, not featured evidence
headache 11.4% (placebo 4.5%)
upper respiratory tract infection 9.6% (placebo 6.3%)
bronchitis 5.3% (placebo 2.7%)
NCT01743001 · Phase 3 · registry result, not featured evidence
oedema peripheral 17.6%
headache 12.7%
dyspnoea 12%
NCT01841762 · Phase 3 · registry result, not featured evidence

Notes

  1. aTrial phases differ: Phase 4 versus Phase 3.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTreatment context has not been resolved for both arms.
  4. dAssessment timepoints differ: 12 weeks versus 26 weeks.
  5. eThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  6. fPopulation context differs: registered conditions differ.
  7. gAssessment timepoints differ: 12 weeks versus 16 weeks.
  8. hTrial phases differ: Phase 3 versus Phase 4.
  9. iAssessment timepoints differ: 78 weeks versus 26 weeks.
  10. jPopulation comparability has not been reviewed for these studies.
  11. kPopulation comparability has not been reviewed for 5 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Bosentan

Time to First Clinical Worsening Event 96.1% (n=159) vs 90.6% (n=175) placebo @ 17wk
absolute value · percentage points
Kaplan-Meier estimate at Month 4
NCT00303459 · Phase 4 · registry result, not featured evidence
show 1 more result
97.4% (n=159) vs 95.3% (n=175) placebo @ 17wk
Kaplan-Meier estimate at Month 4
NCT00303459 · Phase 4 · registry result, not featured evidence
Time to First Clinical Worsening Event 90.5% (n=159) vs 83% (n=175) placebo @ 35wk
absolute value · percentage points
Kaplan-Meier estimate at Month 8
NCT00303459 · Phase 4 · registry result, not featured evidence
show 1 more result
94.6% (n=159) vs 91.8% (n=175) placebo @ 35wk
Kaplan-Meier estimate at Month 8
NCT00303459 · Phase 4 · registry result, not featured evidence
Time to First Clinical Worsening Event 82.7% (n=159) vs 74% (n=175) placebo @ 52wk
absolute value · percentage points
Kaplan-Meier estimate at Month 12
NCT00303459 · Phase 4 · registry result, not featured evidence
show 1 more result
89.6% (n=159) vs 88.8% (n=175) placebo @ 52wk
Kaplan-Meier estimate at Month 12
NCT00303459 · Phase 4 · registry result, not featured evidence
Time to First Clinical Worsening Event 74.7% (n=159) vs 71% (n=175) placebo @ 69wk
absolute value · percentage points
Kaplan-Meier estimate at Month 16
NCT00303459 · Phase 4 · registry result, not featured evidence
show 1 more result
85.3% (n=159) vs 86.9% (n=175) placebo @ 69wk
Kaplan-Meier estimate at Month 16
NCT00303459 · Phase 4 · registry result, not featured evidence
Time to First Clinical Worsening Event 71.8% (n=159) vs 66.1% (n=175) placebo @ 87wk
absolute value · percentage points
Kaplan-Meier estimate at Month 20
NCT00303459 · Phase 4 · registry result, not featured evidence
show 1 more result
82.3% (n=159) vs 83.8% (n=175) placebo @ 87wk
Kaplan-Meier estimate at Month 20
NCT00303459 · Phase 4 · registry result, not featured evidence
Time to First Clinical Worsening Event 66.6% (n=159) vs 61.5% (n=175) placebo @ 104wk
absolute value · percentage points
Kaplan-Meier estimate at Month 24
NCT00303459 · Phase 4 · registry result, not featured evidence
show 1 more result
76.9% (n=159) vs 79.8% (n=175) placebo @ 104wk
Kaplan-Meier estimate at Month 24
NCT00303459 · Phase 4 · registry result, not featured evidence
Time to First Clinical Worsening Event 65.8% (n=159) vs 55% (n=175) placebo @ 121wk
absolute value · percentage points
Kaplan-Meier estimate at Month 28
NCT00303459 · Phase 4 · registry result, not featured evidence
show 1 more result
76.1% (n=159) vs 74.7% (n=175) placebo @ 121wk
Kaplan-Meier estimate at Month 28
NCT00303459 · Phase 4 · registry result, not featured evidence
Time to First Clinical Worsening Event 62.4% (n=159) vs 52.7% (n=175) placebo @ 139wk
absolute value · percentage points
Kaplan-Meier estimate at Month 32
NCT00303459 · Phase 4 · registry result, not featured evidence
show 1 more result
75.2% (n=159) vs 73.1% (n=175) placebo @ 139wk
Kaplan-Meier estimate at Month 32
NCT00303459 · Phase 4 · registry result, not featured evidence
Time to First Clinical Worsening Event 57.5% (n=159) vs 48.8% (n=175) placebo @ 147wk
absolute value · percentage points
Kaplan-Meier estimate at Month 34
NCT00303459 · Phase 4 · registry result, not featured evidence
Time to First Clinical Worsening Event 56.4% (n=159) vs 48% (n=175) placebo @ 173wk
absolute value · percentage points
Kaplan-Meier estimate at Month 40
NCT00303459 · Phase 4 · registry result, not featured evidence
show 1 more result
72.2% (n=159) vs 61.9% (n=175) placebo @ 173wk
Kaplan-Meier estimate at Month 40
NCT00303459 · Phase 4 · registry result, not featured evidence
Time to First Clinical Worsening Event 50.6% (n=159) vs 46.2% (n=175) placebo @ 191wk
absolute value · percentage points
Kaplan-Meier estimate at Month 44
NCT00303459 · Phase 4 · registry result, not featured evidence
show 1 more result
64.2% (n=159) vs 60.1% (n=175) placebo @ 191wk
Kaplan-Meier estimate at Month 44
NCT00303459 · Phase 4 · registry result, not featured evidence
Time to First Clinical Worsening Event 46.7% (n=159) vs 45.2% (n=175) placebo @ 208wk
absolute value · percentage points
Kaplan-Meier estimate at Month 48
NCT00303459 · Phase 4 · registry result, not featured evidence
show 1 more result
60.3% (n=159) vs 58.1% (n=175) placebo @ 208wk
Kaplan-Meier estimate at Month 48
NCT00303459 · Phase 4 · registry result, not featured evidence

+ 44 further endpoints in the CSV export.

Macitentan

PAH Morbidity/Mortality Composite 92.7% (n=242) vs 80.1% (n=250) placebo @ 26wk10 mg
absolute value · percentage points
NCT00660179 · Phase 3 · monotherapy · Pulmonary Arterial Hypertension · phase 3
show 11 more results
85.5% (n=242) vs 71.4% (n=250) placebo @ 52wk10 mg
NCT00660179 · Phase 3 · monotherapy · Pulmonary Arterial Hypertension · phase 3
79.9% (n=242) vs 61.5% (n=250) placebo @ 78wk10 mg
NCT00660179 · Phase 3 · monotherapy · Pulmonary Arterial Hypertension · phase 3
74.3% (n=242) vs 57.3% (n=250) placebo @ 104wk10 mg
NCT00660179 · Phase 3 · monotherapy · Pulmonary Arterial Hypertension · phase 3
70% (n=242) vs 50.2% (n=250) placebo @ 130wk10 mg
NCT00660179 · Phase 3 · monotherapy · Pulmonary Arterial Hypertension · phase 3
63.2% (n=242) vs 47% (n=250) placebo @ 156wk10 mg
NCT00660179 · Phase 3 · monotherapy · Pulmonary Arterial Hypertension · phase 3
89.3% (n=250) vs 80.1% (n=250) placebo @ 26wk3 mg
NCT00660179 · Phase 3 · monotherapy · Pulmonary Arterial Hypertension · phase 3
81.6% (n=250) vs 71.4% (n=250) placebo @ 52wk3 mg
NCT00660179 · Phase 3 · monotherapy · Pulmonary Arterial Hypertension · phase 3
72.5% (n=250) vs 61.5% (n=250) placebo @ 78wk3 mg
NCT00660179 · Phase 3 · monotherapy · Pulmonary Arterial Hypertension · phase 3
65.5% (n=250) vs 57.3% (n=250) placebo @ 104wk3 mg
NCT00660179 · Phase 3 · monotherapy · Pulmonary Arterial Hypertension · phase 3
61.9% (n=250) vs 50.2% (n=250) placebo @ 130wk3 mg
NCT00660179 · Phase 3 · monotherapy · Pulmonary Arterial Hypertension · phase 3
55% (n=250) vs 47% (n=250) placebo @ 156wk3 mg
NCT00660179 · Phase 3 · monotherapy · Pulmonary Arterial Hypertension · phase 3
PAH Hospitalization or Death Composite 94.6% (n=242) vs 84.8% (n=250) placebo @ 26wk10 mg
absolute value · percentage points
NCT00660179 · Phase 3 · monotherapy · Pulmonary Arterial Hypertension · phase 3
show 11 more results
89.8% (n=242) vs 76.7% (n=250) placebo @ 52wk10 mg
NCT00660179 · Phase 3 · monotherapy · Pulmonary Arterial Hypertension · phase 3
84.8% (n=242) vs 69% (n=250) placebo @ 78wk10 mg
NCT00660179 · Phase 3 · monotherapy · Pulmonary Arterial Hypertension · phase 3
81.7% (n=242) vs 67.9% (n=250) placebo @ 104wk10 mg
NCT00660179 · Phase 3 · monotherapy · Pulmonary Arterial Hypertension · phase 3
77.9% (n=242) vs 62% (n=250) placebo @ 130wk10 mg
NCT00660179 · Phase 3 · monotherapy · Pulmonary Arterial Hypertension · phase 3
70.6% (n=242) vs 55.4% (n=250) placebo @ 156wk10 mg
NCT00660179 · Phase 3 · monotherapy · Pulmonary Arterial Hypertension · phase 3
90.8% (n=250) vs 84.8% (n=250) placebo @ 26wk3 mg
NCT00660179 · Phase 3 · monotherapy · Pulmonary Arterial Hypertension · phase 3
84.9% (n=250) vs 76.7% (n=250) placebo @ 52wk3 mg
NCT00660179 · Phase 3 · monotherapy · Pulmonary Arterial Hypertension · phase 3
78.1% (n=250) vs 69% (n=250) placebo @ 78wk3 mg
NCT00660179 · Phase 3 · monotherapy · Pulmonary Arterial Hypertension · phase 3
75.1% (n=250) vs 67.9% (n=250) placebo @ 104wk3 mg
NCT00660179 · Phase 3 · monotherapy · Pulmonary Arterial Hypertension · phase 3
70.3% (n=250) vs 62% (n=250) placebo @ 130wk3 mg
NCT00660179 · Phase 3 · monotherapy · Pulmonary Arterial Hypertension · phase 3
67.1% (n=250) vs 55.4% (n=250) placebo @ 156wk3 mg
NCT00660179 · Phase 3 · monotherapy · Pulmonary Arterial Hypertension · phase 3
All-cause Mortality 97.4% (n=242) vs 95.2% (n=250) placebo @ 26wk10 mg
absolute value · percentage points
NCT00660179 · Phase 3 · monotherapy · Pulmonary Arterial Hypertension · phase 3
show 23 more results
96.4% (n=242) vs 93.6% (n=250) placebo @ 52wk10 mg
NCT00660179 · Phase 3 · monotherapy · Pulmonary Arterial Hypertension · phase 3
94.8% (n=242) vs 92.4% (n=250) placebo @ 78wk10 mg
NCT00660179 · Phase 3 · monotherapy · Pulmonary Arterial Hypertension · phase 3
94.8% (n=242) vs 91.7% (n=250) placebo @ 104wk10 mg
NCT00660179 · Phase 3 · monotherapy · Pulmonary Arterial Hypertension · phase 3
93.3% (n=242) vs 89.8% (n=250) placebo @ 130wk10 mg
NCT00660179 · Phase 3 · monotherapy · Pulmonary Arterial Hypertension · phase 3
93.3% (n=242) vs 89.8% (n=250) placebo @ 156wk10 mg
NCT00660179 · Phase 3 · monotherapy · Pulmonary Arterial Hypertension · phase 3
96.3% (n=242) vs 94.7% (n=250) placebo @ 26wk10 mg
NCT00660179 · Phase 3 · monotherapy · Pulmonary Arterial Hypertension · phase 3
95% (n=242) vs 91.4% (n=250) placebo @ 52wk10 mg
NCT00660179 · Phase 3 · monotherapy · Pulmonary Arterial Hypertension · phase 3
93.3% (n=242) vs 89.3% (n=250) placebo @ 78wk10 mg
NCT00660179 · Phase 3 · monotherapy · Pulmonary Arterial Hypertension · phase 3
89.1% (n=242) vs 87.2% (n=250) placebo @ 104wk10 mg
NCT00660179 · Phase 3 · monotherapy · Pulmonary Arterial Hypertension · phase 3
86.9% (n=242) vs 82.6% (n=250) placebo @ 130wk10 mg
NCT00660179 · Phase 3 · monotherapy · Pulmonary Arterial Hypertension · phase 3
82.9% (n=242) vs 80.7% (n=250) placebo @ 156wk10 mg
NCT00660179 · Phase 3 · monotherapy · Pulmonary Arterial Hypertension · phase 3
97.1% (n=250) vs 95.2% (n=250) placebo @ 26wk3 mg
NCT00660179 · Phase 3 · monotherapy · Pulmonary Arterial Hypertension · phase 3
95.6% (n=250) vs 93.6% (n=250) placebo @ 52wk3 mg
NCT00660179 · Phase 3 · monotherapy · Pulmonary Arterial Hypertension · phase 3
94.6% (n=250) vs 92.4% (n=250) placebo @ 78wk3 mg
NCT00660179 · Phase 3 · monotherapy · Pulmonary Arterial Hypertension · phase 3
91.7% (n=250) vs 91.7% (n=250) placebo @ 104wk3 mg
NCT00660179 · Phase 3 · monotherapy · Pulmonary Arterial Hypertension · phase 3
89.9% (n=250) vs 89.8% (n=250) placebo @ 130wk3 mg
NCT00660179 · Phase 3 · monotherapy · Pulmonary Arterial Hypertension · phase 3
87.3% (n=250) vs 89.8% (n=250) placebo @ 156wk3 mg
NCT00660179 · Phase 3 · monotherapy · Pulmonary Arterial Hypertension · phase 3
96.4% (n=250) vs 94.7% (n=250) placebo @ 26wk3 mg
NCT00660179 · Phase 3 · monotherapy · Pulmonary Arterial Hypertension · phase 3
93.9% (n=250) vs 91.4% (n=250) placebo @ 52wk3 mg
NCT00660179 · Phase 3 · monotherapy · Pulmonary Arterial Hypertension · phase 3
91.4% (n=250) vs 89.3% (n=250) placebo @ 78wk3 mg
NCT00660179 · Phase 3 · monotherapy · Pulmonary Arterial Hypertension · phase 3
87.3% (n=250) vs 87.2% (n=250) placebo @ 104wk3 mg
NCT00660179 · Phase 3 · monotherapy · Pulmonary Arterial Hypertension · phase 3
83.4% (n=250) vs 82.6% (n=250) placebo @ 130wk3 mg
NCT00660179 · Phase 3 · monotherapy · Pulmonary Arterial Hypertension · phase 3
80% (n=250) vs 80.7% (n=250) placebo @ 156wk3 mg
NCT00660179 · Phase 3 · monotherapy · Pulmonary Arterial Hypertension · phase 3
WHO Functional Class Improvement 22.3% (n=242) vs 12.9% (n=249) placebo @ 26wk10 mg
event count · % of participants
NCT00660179 · Phase 3 · monotherapy · Pulmonary Arterial Hypertension · phase 3 · converted to % from 54 participants as posted
show 1 more result
19.8% (n=248) vs 12.9% (n=249) placebo @ 26wk*3 mg
NCT00660179 · Phase 3 · monotherapy · Pulmonary Arterial Hypertension · phase 3 · converted to % from 49 participants as posted
PVR Change 680 vs 1042 placebo (dyn*sec/cm^5) @ 26wk10 mg
absolute change · (dyn*sec/cm^5)
NCT00660179 · Phase 3 · monotherapy · Pulmonary Arterial Hypertension · phase 3
show 1 more result
736 vs 1042 placebo (dyn*sec/cm^5) @ 26wk3 mg
NCT00660179 · Phase 3 · monotherapy · Pulmonary Arterial Hypertension · phase 3
RVSV Change 15.17 mL @ 26wk10 mg
absolute change · mL
No placebo or comparator arm
NCT02310672 · Phase 4 · registry result, not featured evidence
PVR 0.63 ratio @ 26wk10 mg
ratio to baseline · ratio
No placebo or comparator arm
NCT02310672 · Phase 4 · registry result, not featured evidence
RVEDV Change -6.22 mL @ 26wk10 mg
absolute change · mL
No placebo or comparator arm
NCT02310672 · Phase 4 · registry result, not featured evidence
RVESV Change -16.39 mL @ 26wk10 mg
absolute change · mL
No placebo or comparator arm
NCT02310672 · Phase 4 · registry result, not featured evidence
RVEF 10.14% (n=72) @ 26wk10 mg
absolute change · percentage points
No placebo or comparator arm
NCT02310672 · Phase 4 · registry result, not featured evidence
RV Mass Change -10.1 g @ 26wk10 mg
absolute change · g
No placebo or comparator arm
NCT02310672 · Phase 4 · registry result, not featured evidence
6MWD - Change 38.85 m @ 26wk10 mg
absolute change · m
No placebo or comparator arm
NCT02310672 · Phase 4 · registry result, not featured evidence
show 2 more results
4.897 m @ 24wk
NCT05167825 · Phase 3 · registry result, not featured evidence
24.71 m @ 52wk
NCT05167825 · Phase 3 · registry result, not featured evidence

+ 31 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Bosentan's landscape · Macitentan's landscape